A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: Safety and efficacy of combination therapy with imatinib and cyclophosphamide

Rheumatology

Volumn 48, Issue 1, 2009, Pages 49-52

  Sabnani, I ^a   Zucker, M J ^a   Rosenstein, E D ^b   Baran, D A ^a   Arroyo, L H ^a   Tsang, P ^a   Zubair, M ^a   Rivera, V ^a  

^a NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^b SAINT BARNABAS MEDICAL CENTER   (United States)

Author keywords

Anti fibrotic therapy; Imatinib; Intravenous cyclophosphamide in interstitial lung disease; PDGF receptor inhibitor; Pulmonary arterial hypertension; Scleroderma related interstitial lung disease; Systemic sclerosis; Treatment of interstitial lung disease

Indexed keywords

BOSENTAN; CYCLOPHOSPHAMIDE; DIURETIC AGENT; GAMMA INTERFERON; IMATINIB;

ADULT; ARTICLE; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LIVER FUNCTION; LUNG FUNCTION; LUNG TRANSPLANTATION; MALE; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; SYSTEMIC SCLEROSIS; TREATMENT DURATION;

ADULT; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 57349198200     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken369     Document Type: Article

References (29)

1. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283-9.
2. Owens GR, Fino GJ, Herbert DL et al. Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma. Chest 1983;84:546-50.
3. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004;140:37-50.
4. Leask A, Holmes A, Abraham DJ. Connective tissue growth factor: A new and important player in the pathogenesis of fibrosis. Curr Rheumatol Rep 2002;4:136-42.
5. Baroni SS, Santillo M, Bevilacqua F et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354:2667-76.
6. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132:947-54.
7. Tashkin DP, Elashoff R, Clements PJ et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
8. Giacomelli R, Valentini G, Salsano F et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002;29:731-6.
9. Airò P, Danieli E, Parrinello G et al. Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results. Clin Exp Rheumatol 2004;22:573-2.
10. Kerkelä R, Grazette L, Yacobi R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-16.
11. Paniagua RT, Sharpe O, Ho PP et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 2006;116:2633-42.
12. Schermuly RT, Dony E, Ghofrani HA et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811-21.
13. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005;353:1412-3.
14. Abdollahi A, Li M, Ping G et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 2005;201:925-35.
15. Daniels CE, Wilkes MC, Edens M et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004;114:1308-16.
16. Distler JH, Jüngel A, Huber LC et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007;56:311-22.
17. Wollheim FA. Treatment of pulmonary fibrosis in systemic sclerosis: light at the end of the tunnel? Arthritis Rheum 2007;56:9-12.
18. Preliminary criteria for the classification of systematic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American rheumatism association diagnostic and therapeutic criteria committee. Arthritis Rheum 1980;23:581-90.
19. Knight J, Murphy TM, Browning I. The lung in sickle cell disease. Pediatr Pulmonol 1999;28:205-16.
20. Morgan C, Knight C, Lunt M, Black CM, Silman AJ. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 2003;62:146-50.
21. Highland KB, Silver RM. New developments in scleroderma interstitial lung disease. Curr Opin Rheumatol 2005;17:737-45.
22. Latsi PI, Wells AU. Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol 2003;15:748-55.
23. Strand V. Predictors and outcomes of scleroderma renal crisis: Data from the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002;46:2836-7.
24. Seibold JR, Korn JH, Simms R et al. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000;132:871-9.
25. Sfikakis PP, Gorgoulis VG, Katsiari CG, Evangelou K, Kostopoulos C, Black CM. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology 2008;47:735-7.
26. Martinez FJ, McCune WJ. Cyclophosphamide for scleroderma lung disease. N Engl J Med 2006;354:2707-9.
27. Zamora AC, Wolters PJ, Collard HR et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 2008;102:150-5.
28. Liossis SN, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology 2006;45:1005-8.
29. Nash RA, McSweeney PA, Crofford LJ et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: Long-term follow-up of the US multicenter pilot study. Blood 2007;110: 1388-96.